FRANKLIN LAKES, N.J., Feb. 5, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31, 2018. This represents an increase of 35.1 percent from the prior-year period, which is primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis, revenues increased 5.2 percent over the prior-year period.
“We are very pleased with our strong start to fiscal year 2019. As noted in our pre-announcement, results were better than expected across all three segments,” said Vincent A. Forlenza, Chairman and CEO. “It is evident that the combination of BD and C. R. Bard is delivering value to customers, patients and shareholders around the world.”
First Quarter Fiscal 2019 Operating Results
As reported, diluted earnings per share for the first quarter were $2.05, compared with $(0.76) in the prior-year period. This represents an increase of 369.7 percent and is primarily due to the gain on the sale of the Advanced Bioprocessing business, and net expense related to U.S. tax reform in the prior-year period. Adjusted diluted earnings per share were $2.70, compared with $2.48 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 8.9 percent, or 14.9 percent on a currency-neutral basis.
Segment Results
In the BD Medical segment, as reported, worldwide revenues for the quarter of $2.135 billion increased 15.3 percent from the prior-year period, primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis, BD Medical revenues increased 5.2 percent over the prior-year period. The segment’s results were driven by strong performance in the Medication Management Solutions and Pharmaceutical Systems units.
In the BD Life Sciences segment, as reported, worldwide revenues for the quarter were $1.056 billion. This represents an increase of 1.0 percent over the prior-year period. On a comparable, currency-neutral basis that excludes the revenues associated with the divested Advanced Bioprocessing business, BD Life Sciences revenues of $1.047 billion increased 4.7 percent over the prior-year period. Revenue growth was primarily driven by strong performance in the Preanalytical Systems unit.
In the BD Interventional segment, as reported, worldwide revenues for the quarter were $0.970 billion. On a comparable, currency-neutral basis, revenues increased 5.7 percent over the prior-year period. The segment’s results reflect strong performance in the Surgery and Urology and Critical Care units. Growth in the Peripheral Intervention unit reflects a tough comparison to the prior-year period.
Geographic Results
As reported, first quarter revenues in the U.S. of $2.387 billion increased 44.1 percent from the prior-year period, primarily due to the acquisition of C. R. Bard. On a comparable basis, U.S. revenues increased 6.0 percent over the prior-year period. Growth in the U.S. was driven by strong performance from all three segments.
As reported, revenues outside of the U.S. of $1.773 billion increased 24.6 percent from the prior-year period, primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis, revenues outside of the U.S. increased 4.1 percent over the prior-year period. International revenue growth was driven by strong performance in China and the rest of Asia, as well as Latin America.
Fiscal 2019 Outlook for Full Year
The company reaffirms previously issued fiscal year 2019 revenue and adjusted diluted earnings per share guidance.
As reported, the company expects full fiscal year 2019 revenues to increase 8.5 to 9.5 percent, primarily due to the C. R. Bard acquisition. The company estimates full fiscal year 2019 revenues will increase 5.0 to 6.0 percent on a comparable, currency-neutral basis.
The company expects adjusted diluted earnings per share to be between $12.05 and $12.15, resulting in growth of approximately 13.0 to 14.0 percent on a currency-neutral basis. This represents growth of approximately 10.0 percent, including the estimated unfavorable impact of foreign currency, over fiscal 2018 adjusted diluted earnings per share of $11.01.
Estimated adjusted diluted earnings per share for fiscal 2019 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking non-GAAP earnings guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of BD’s financial performance.
Conference Call Information
A conference call regarding BD’s first quarter results will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, February 5, 2019. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, February 12, 2019, confirmation number 7064558.
Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.
All “comparable” basis revenue growth rates relating to fiscal year 2019 presented throughout this release include, where applicable, the results of C. R. Bard, Inc. (“Bard”) in the prior-year period, and also include adjustments for certain items as detailed in the attached tables. Beginning in the second quarter of fiscal year 2018, the Company’s organizational structure was based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Interventional segment was added upon the Company’s completion of its acquisition of Bard, and this new segment includes the majority of Bard’s product offerings and certain product offerings that were previously reported in the Medical segment. Certain of Bard’s product offerings are included under the Company’s Medical segment, specifically within the new Medication Delivery Solutions unit, which was formerly the Medical segment’s Medication and Procedural Solutions unit. Prior-year amounts have been revised to reflect the movement of certain product offerings that were previously reported in the Medical segment and that are now reported in the Interventional segment, as discussed above. Current and prior-year adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs; and the loss on debt extinguishment. We also provide these measures on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. Reconciliations of these amounts to the most directly comparable GAAP measures are included in the tables at the end of this release.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
***
This press release, including the section entitled “Fiscal 2019 Outlook for Full Year”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These factors include, but are not limited to: risks relating to the integration of the C.R. Bard operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; new or changing laws and regulations impacting our business (including the imposition of tariffs or changes in laws impacting international trade) or changes in enforcement practices with respect to such laws; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; legislative or regulatory changes to the U.S. healthcare system, potential cuts in governmental healthcare spending or measures to contain healthcare costs, each of which could result in reduced demand for our products or downward pricing pressure; changes in interest or foreign currency exchange rates; adverse changes in regional, national or foreign economic conditions, particularly in emerging markets, including any impact on our ability to access credit markets and finance our operations, the demand for our products and services, utilization rates or otherwise, or our suppliers’ ability to provide products needed for our operations; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; interruptions in our supply chain or manufacturing processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; product efficacy or safety concerns resulting in product recalls or actions being taken by the FDA or other regulators; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform outside the U.S., including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
Contact:
Monique N. Dolecki, Investor Relations – 201-847-5378
Kristen Cardillo, Corporate Communications – 201-847-5657
|
BECTON DICKINSON AND COMPANY |
|||||||||||
|
CONSOLIDATED INCOME STATEMENTS |
|||||||||||
|
(Unaudited; Amounts in millions, except share and per share data) |
|||||||||||
|
Three Months Ended December 31, |
|||||||||||
|
2018 |
2017 |
% Change |
|||||||||
|
REVENUES |
$ |
4,160 |
$ |
3,080 |
35.1 |
||||||
|
Cost of products sold |
2,187 |
1,527 |
43.2 |
||||||||
|
Selling and administrative expense |
1,073 |
773 |
38.9 |
||||||||
|
Research and development expense |
258 |
191 |
34.8 |
||||||||
|
Acquisitions and other restructurings |
91 |
354 |
(74.4) |
||||||||
|
Other operating income, net |
(335) |
— |
100.0 |
||||||||
|
TOTAL OPERATING COSTS AND EXPENSES |
3,273 |
2,845 |
15.1 |
||||||||
|
OPERATING INCOME |
888 |
235 |
277.3 |
||||||||
|
Interest expense |
(171) |
(158) |
7.7 |
||||||||
|
Interest income, net |
(12) |
44 |
(128.3) |
||||||||
|
Other income (expense), net |
10 |
(16) |
163.6 |
||||||||
|
INCOME BEFORE INCOME TAXES |
714 |
105 |
580.7 |
||||||||
|
Income tax provision |
115 |
241 |
(52.4) |
||||||||
|
NET INCOME (LOSS) |
599 |
(136) |
539.3 |
||||||||
|
Preferred stock dividends |
(38) |
(38) |
— |
||||||||
|
NET INCOME (LOSS) APPLICABLE TO COMMON SHAREHOLDERS |
$ |
562 |
$ |
(174) |
422.1 |
||||||
|
EARNINGS PER SHARE |
|||||||||||
|
Basic Earnings (Loss) per Share |
$ |
2.09 |
$ |
(0.76) |
375.0 |
||||||
|
Diluted Earnings (Loss) per Share |
$ |
2.05 |
$ |
(0.76) |
369.7 |
||||||
|
AVERAGE SHARES OUTSTANDING (in thousands) |
|||||||||||
|
Basic |
269,035 |
230,038 |
|||||||||
|
Diluted |
274,256 |
230,038 |
|||||||||
|
BECTON DICKINSON AND COMPANY |
||||||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
|
(Amounts in millions) |
||||||||
|
December 31, 2018 |
September 30, 2018 |
|||||||
|
(Unaudited) |
||||||||
|
ASSETS |
||||||||
|
Cash and equivalents |
$ |
943 |
$ |
1,140 |
||||
|
Restricted cash |
98 |
96 |
||||||
|
Short-term investments |
5 |
17 |
||||||
|
Trade receivables, net |
2,216 |
2,319 |
||||||
|
Inventories |
2,522 |
2,451 |
||||||
|
Assets held for sale |
— |
137 |
||||||
|
Prepaid expenses and other |
1,157 |
1,251 |
||||||
|
TOTAL CURRENT ASSETS |
6,941 |
7,411 |
||||||
|
Property, plant and equipment, net |
5,362 |
5,375 |
||||||
|
Goodwill and other intangibles, net |
39,567 |
40,041 |
||||||
|
Other Assets |
1,062 |
1,078 |
||||||
|
TOTAL ASSETS |
$ |
52,932 |
$ |
53,904 |
||||
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
|
Short-term debt |
$ |
3,254 |
$ |
2,601 |
||||
|
Other current liabilities |
3,891 |
4,615 |
||||||
|
Long-term debt |
17,817 |
18,894 |
||||||
|
Long-term employee benefit obligations |
805 |
1,056 |
||||||
|
Deferred income taxes and other |
5,762 |
5,743 |
||||||
|
Shareholders’ equity |
21,404 |
20,994 |
||||||
|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ |
52,932 |
$ |
53,904 |
||||
|
BECTON DICKINSON AND COMPANY |
||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
|
(Unaudited; Amounts in millions) |
||||||||
|
Three Months Ended December 31, |
||||||||
|
2018 |
2017 |
|||||||
|
OPERATING ACTIVITIES |
||||||||
|
Net income (loss) |
$ |
599 |
$ |
(136) |
||||
|
Depreciation and amortization |
563 |
291 |
||||||
|
Change in operating assets and liabilities and other, net |
(918) |
166 |
||||||
|
NET CASH PROVIDED BY OPERATING ACTIVITIES |
245 |
320 |
||||||
|
INVESTING ACTIVITIES |
||||||||
|
Capital expenditures |
(167) |
(178) |
||||||
|
Acquisitions of businesses, net of cash acquired |
— |
(14,900) |
||||||
|
Proceeds from divestitures, net |
476 |
— |
||||||
|
Other, net |
(9) |
(125) |
||||||
|
NET CASH PROVIDED BY (USED FOR) INVESTING ACTIVITIES |
299 |
(15,203) |
||||||
|
FINANCING ACTIVITIES |
||||||||
|
Change in credit facility borrowings |
50 |
— |
||||||
|
Proceeds from long-term debt and term loans |
— |
2,250 |
||||||
|
Payments of debt and term loans |
(453) |
— |
||||||
|
Dividends paid |
(245) |
(210) |
||||||
|
Other, net |
(86) |
(101) |
||||||
|
NET CASH (USED FOR) PROVIDED BY FINANCING ACTIVITIES |
(734) |
1,938 |
||||||
|
Effect of exchange rate changes on cash and equivalents and restricted cash |
(5) |
2 |
||||||
|
NET DECREASE IN CASH AND EQUIVALENTS AND RESTRICTED CASH |
(195) |
(12,943) |
||||||
|
OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH |
1,236 |
14,179 |
||||||
|
CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH |
$ |
1,042 |
$ |
1,236 |
||||
|
BECTON DICKINSON AND COMPANY |
|||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION |
|||||||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS – UNITED STATES |
|||||||||||
|
Three Months Ended December 31, |
|||||||||||
|
(Unaudited; Amounts in millions) |
|||||||||||
|
A |
B |
C=(A-B)/B |
|||||||||
|
2018 |
2017 |
% Change |
|||||||||
|
BD MEDICAL |
|||||||||||
|
Medication Delivery Solutions (a) |
$ |
520 |
$ |
370 |
40.5 |
||||||
|
Medication Management Solutions |
506 |
471 |
7.5 |
||||||||
|
Diabetes Care |
145 |
146 |
(0.5) |
||||||||
|
Pharmaceutical Systems |
68 |
54 |
26.8 |
||||||||
|
TOTAL |
$ |
1,239 |
$ |
1,040 |
19.1 |
||||||
|
BD LIFE SCIENCES |
|||||||||||
|
Preanalytical Systems |
$ |
201 |
$ |
184 |
8.8 |
||||||
|
Diagnostic Systems |
175 |
167 |
5.2 |
||||||||
|
Biosciences |
108 |
108 |
(0.2) |
||||||||
|
TOTAL |
$ |
484 |
$ |
459 |
5.4 |
||||||
|
BD INTERVENTIONAL |
|||||||||||
|
Surgery (a) |
$ |
275 |
$ |
152 |
NM |
||||||
|
Peripheral Intervention (a) |
191 |
5 |
NM |
||||||||
|
Urology and Critical Care |
197 |
— |
NM |
||||||||
|
TOTAL |
$ |
664 |
$ |
157 |
NM |
||||||
|
TOTAL UNITED STATES |
$ |
2,387 |
$ |
1,657 |
44.1 |
||||||
|
(a) |
The presentation of prior-period amounts reflects a reclassification of $157 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment. |
|
BECTON DICKINSON AND COMPANY |
||||||||||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION |
||||||||||||||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS – INTERNATIONAL |
||||||||||||||||||
|
Three Months Ended December 31, (continued) |
||||||||||||||||||
|
(Unaudited; Amounts in millions) |
||||||||||||||||||
|
D=(A-B)/B |
E=(A-B-C)/B |
|||||||||||||||||
|
A |
B |
C |
% Change |
|||||||||||||||
|
2018 |
2017 |
FX Impact |
Reported |
FXN |
||||||||||||||
|
BD MEDICAL |
||||||||||||||||||
|
Medication Delivery Solutions (a) |
$ |
438 |
$ |
372 |
$ |
(20) |
17.7 |
23.0 |
||||||||||
|
Medication Management Solutions |
118 |
116 |
(3) |
1.1 |
3.8 |
|||||||||||||
|
Diabetes Care |
129 |
132 |
(5) |
(2.2) |
1.5 |
|||||||||||||
|
Pharmaceutical Systems |
212 |
192 |
(4) |
10.5 |
12.6 |
|||||||||||||
|
TOTAL |
$ |
896 |
$ |
811 |
$ |
(32) |
10.4 |
14.3 |
||||||||||
|
BD LIFE SCIENCES |
||||||||||||||||||
|
Preanalytical Systems |
$ |
192 |
$ |
191 |
$ |
(9) |
0.8 |
5.4 |
||||||||||
|
Diagnostic Systems |
207 |
214 |
(7) |
(3.6) |
(0.2) |
|||||||||||||
|
Biosciences |
173 |
181 |
(5) |
(4.3) |
(1.6) |
|||||||||||||
|
TOTAL |
$ |
572 |
$ |
586 |
$ |
(21) |
(2.4) |
1.2 |
||||||||||
|
BD INTERVENTIONAL |
||||||||||||||||||
|
Surgery (a) |
$ |
73 |
$ |
25 |
$ |
(2) |
NM |
NM |
||||||||||
|
Peripheral Intervention (a) |
145 |
1 |
(5) |
NM |
NM |
|||||||||||||
|
Urology and Critical Care |
88 |
— |
(2) |
NM |
NM |
|||||||||||||
|
TOTAL |
$ |
306 |
$ |
26 |
$ |
(9) |
NM |
NM |
||||||||||
|
TOTAL INTERNATIONAL |
$ |
1,773 |
$ |
1,423 |
$ |
(62) |
24.6 |
28.9 |
||||||||||
|
(a) |
The presentation of prior-period amounts reflects a reclassification of $26 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment. |
|
BECTON DICKINSON AND COMPANY |
||||||||||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION |
||||||||||||||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS – TOTAL |
||||||||||||||||||
|
Three Months Ended December 31, (continued) |
||||||||||||||||||
|
(Unaudited; Amounts in millions) |
||||||||||||||||||
|
D=(A-B)/B |
E=(A-B-C)/B |
|||||||||||||||||
|
A |
B |
C |
% Change |
|||||||||||||||
|
2018 |
2017 |
FX Impact |
Reported |
FXN |
||||||||||||||
|
BD MEDICAL |
||||||||||||||||||
|
Medication Delivery Solutions (a) |
$ |
958 |
$ |
742 |
$ |
(20) |
29.1 |
31.7 |
||||||||||
|
Medication Management Solutions |
624 |
587 |
(3) |
6.2 |
6.7 |
|||||||||||||
|
Diabetes Care |
274 |
277 |
(5) |
(1.3) |
0.5 |
|||||||||||||
|
Pharmaceutical Systems |
280 |
245 |
(4) |
14.0 |
15.7 |
|||||||||||||
|
TOTAL |
$ |
2,135 |
$ |
1,852 |
$ |
(32) |
15.3 |
17.0 |
||||||||||
|
BD LIFE SCIENCES |
||||||||||||||||||
|
Preanalytical Systems |
$ |
393 |
$ |
375 |
$ |
(9) |
4.7 |
7.1 |
||||||||||
|
Diagnostic Systems |
382 |
381 |
(7) |
0.2 |
2.1 |
|||||||||||||
|
Biosciences |
281 |
289 |
(5) |
(2.8) |
(1.1) |
|||||||||||||
|
TOTAL |
$ |
1,056 |
$ |
1,045 |
$ |
(21) |
1.0 |
3.0 |
||||||||||
|
BD INTERVENTIONAL |
||||||||||||||||||
|
Surgery (a) |
$ |
348 |
$ |
177 |
$ |
(2) |
NM |
NM |
||||||||||
|
Peripheral Intervention (a) |
337 |
6 |
(5) |
NM |
NM |
|||||||||||||
|
Urology and Critical Care |
285 |
— |
(2) |
NM |
NM |
|||||||||||||
|
TOTAL |
$ |
970 |
$ |
183 |
$ |
(9) |
NM |
NM |
||||||||||
|
TOTAL REVENUES |
$ |
4,160 |
$ |
3,080 |
$ |
(62) |
35.1 |
37.1 |
||||||||||
|
(a) |
The presentation of prior-period amounts reflects a reclassification of $183 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment. |
|
BECTON DICKINSON AND COMPANY |
|||||||||||||||||||||||||||||||||||||
|
SUPPLEMENTAL INFORMATION |
|||||||||||||||||||||||||||||||||||||
|
RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE – UNITED STATES |
|||||||||||||||||||||||||||||||||||||
|
Three Months Ended December 31, |
|||||||||||||||||||||||||||||||||||||
|
(Unaudited; Amounts in millions) |
|||||||||||||||||||||||||||||||||||||
|
A |
B |
C=A+B |
D |
E |
F |
G |
H=D+E+F+G |
I=(C-H)/H |
|||||||||||||||||||||||||||||
|
BD Reported |
Divestiture Adjustments (a) |
Comparable |
BD Reported (b) |
Bard Q1 (c) |
Intercompany Adjustment (d) |
Divestiture Adjustments (a) |
Comparable |
Comparable % Change |
|||||||||||||||||||||||||||||
|
2018 |
2018 |
2017 |
2017 |
2017 |
|||||||||||||||||||||||||||||||||
|
BD MEDICAL |
|||||||||||||||||||||||||||||||||||||
|
Medication Delivery Solutions (b) |
$ |
520 |
$ |
— |
$ |
520 |
$ |
370 |
$ |
145 |
$ |
(3) |
$ |
— |
$ |
512 |
1.6 |
||||||||||||||||||||
|
Medication Management Solutions |
506 |
— |
506 |
471 |
— |
— |
— |
471 |
7.5 |
||||||||||||||||||||||||||||
|
Diabetes Care |
145 |
— |
145 |
146 |
— |
— |
— |
146 |
(0.5) |
||||||||||||||||||||||||||||
|
Pharmaceutical Systems |
68 |
— |
68 |
54 |
— |
— |
— |
54 |
26.8 |
||||||||||||||||||||||||||||
|
TOTAL |
$ |
1,239 |
$ |
— |
$ |
1,239 |
$ |
1,040 |
$ |
145 |
$ |
(3) |
$ |
— |
$ |
1,182 |
4.8 |
||||||||||||||||||||
|
BD LIFE SCIENCES |
|||||||||||||||||||||||||||||||||||||
|
Preanalytical Systems |
$ |
201 |
$ |
— |
$ |
201 |
$ |
184 |
$ |
— |
$ |
— |
$ |
— |
$ |
184 |
8.8 |
||||||||||||||||||||
|
Diagnostic Systems |
175 |
— |
175 |
167 |
— |
— |
— |
167 |
5.2 |
||||||||||||||||||||||||||||
|
Biosciences |
108 |
(4) |
105 |
108 |
— |
— |
(10) |
98 |
6.4 |
||||||||||||||||||||||||||||
|
TOTAL |
$ |
484 |
$ |
(4) |
$ |
480 |
$ |
459 |
$ |
— |
$ |
— |
$ |
(10) |
$ |
449 |
6.9 |
||||||||||||||||||||
|
BD INTERVENTIONAL |
|||||||||||||||||||||||||||||||||||||
|
Surgery (b) |
$ |
275 |
$ |
— |
$ |
275 |
$ |
152 |
$ |
105 |
$ |
— |
$ |
(10) |
$ |
247 |
11.3 |
||||||||||||||||||||
|
Peripheral Intervention (b) |
191 |
— |
191 |
5 |
188 |
— |
— |
193 |
(0.6) |
||||||||||||||||||||||||||||
|
Urology and Critical Care |
197 |
— |
197 |
— |
177 |
— |
— |
177 |
11.5 |
||||||||||||||||||||||||||||
|
TOTAL |
$ |
664 |
$ |
— |
$ |
664 |
$ |
157 |
$ |
470 |
$ |
— |
$ |
(10) |
$ |
617 |
7.6 |
||||||||||||||||||||
|
TOTAL UNITED STATES |
$ |
2,387 |
$ |
(4) |
$ |
2,383 |
$ |
1,657 |
$ |
614 |
$ |
(3) |
$ |
(20) |
$ |
2,248 |
6.0 |
||||||||||||||||||||
|
(a) |
The amounts for the quarters ended December 31, 2018 and 2017 include adjustments for BD’s divestiture of its Advanced Bioprocessing business. The amounts for the quarter ended December 31, 2017 also include adjustments for BD’s divestitures of its soft tissue core needle biopsy product line and Bard’s divestiture of its Aspira® product line. |
|
(b) |
Reflects a reclassification of $157 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment. |
|
(c) |
Amounts represent revenues for the quarter ended December 31, 2017. BD reported a Gore royalty amount, which was previously reported as revenues by Bard, as non-operating income in the current-year period. |
|
(d) |
Represents the elimination of revenues from the Medication Delivery Solutions unit which BD previously recognized from Bard as third-party revenues and that would be treated as intercompany revenues in the current-year period. |
|
BECTON DICKINSON AND COMPANY |
|||||||||||||||||||||||||||||||||||||
|
SUPPLEMENTAL INFORMATION |
|||||||||||||||||||||||||||||||||||||
|
RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE – INTERNATIONAL |
|||||||||||||||||||||||||||||||||||||
|
Three Months Ended December 31, (continued) |
|||||||||||||||||||||||||||||||||||||
|
(Unaudited; Amounts in millions) |
|||||||||||||||||||||||||||||||||||||
|
A |
B |
C=A+B |
D |
E |
F |
G=D+E+F |
H |
I=(C-G-H)/G |
|||||||||||||||||||||||||||||
|
BD Reported |
Divestiture Adjustments (a) |
Comparable |
BD Reported (b) |
Bard Q1 (c) |
Divestiture Adjustments (a) |
Comparable |
FX Impact (d) |
FXN % Change |
|||||||||||||||||||||||||||||
|
2018 |
2018 |
2017 |
2017 |
2017 |
|||||||||||||||||||||||||||||||||
|
BD MEDICAL |
|||||||||||||||||||||||||||||||||||||
|
Medication Delivery Solutions (b) |
$ |
438 |
$ |
— |
$ |
438 |
$ |
372 |
$ |
68 |
$ |
— |
$ |
440 |
$ |
(22) |
4.3 |
||||||||||||||||||||
|
Medication Management Solutions |
118 |
— |
118 |
116 |
— |
— |
116 |
(3) |
3.8 |
||||||||||||||||||||||||||||
|
Diabetes Care |
129 |
— |
129 |
132 |
— |
— |
132 |
(5) |
1.8 |
||||||||||||||||||||||||||||
|
Pharmaceutical Systems |
212 |
— |
212 |
192 |
— |
— |
192 |
(4) |
12.6 |
||||||||||||||||||||||||||||
|
TOTAL |
$ |
896 |
$ |
— |
$ |
896 |
$ |
811 |
$ |
68 |
$ |
— |
$ |
880 |
$ |
(34) |
5.7 |
||||||||||||||||||||
|
BD LIFE SCIENCES |
|||||||||||||||||||||||||||||||||||||
|
Preanalytical Systems |
$ |
192 |
$ |
— |
$ |
192 |
$ |
191 |
$ |
— |
$ |
— |
$ |
191 |
$ |
(11) |
6.3 |
||||||||||||||||||||
|
Diagnostic Systems |
207 |
— |
207 |
214 |
— |
— |
214 |
(9) |
0.8 |
||||||||||||||||||||||||||||
|
Biosciences |
173 |
(5) |
168 |
181 |
— |
(10) |
171 |
(6) |
2.0 |
||||||||||||||||||||||||||||
|
TOTAL |
$ |
572 |
$ |
(5) |
$ |
567 |
$ |
586 |
$ |
— |
$ |
(10) |
$ |
576 |
$ |
(26) |
3.0 |
||||||||||||||||||||
|
BD INTERVENTIONAL |
|||||||||||||||||||||||||||||||||||||
|
Surgery (b) |
$ |
73 |
$ |
— |
$ |
73 |
$ |
25 |
$ |
49 |
$ |
(2) |
$ |
71 |
$ |
(2) |
5.4 |
||||||||||||||||||||
|
Peripheral Intervention (b) |
145 |
— |
145 |
1 |
146 |
— |
147 |
(5) |
2.2 |
||||||||||||||||||||||||||||
|
Urology and Critical Care |
88 |
— |
88 |
— |
90 |
— |
90 |
(2) |
(1.0) |
||||||||||||||||||||||||||||
|
TOTAL |
$ |
306 |
$ |
— |
$ |
306 |
$ |
26 |
$ |
285 |
$ |
(2) |
$ |
309 |
$ |
(9) |
2.0 |
||||||||||||||||||||
|
TOTAL INTERNATIONAL |
$ |
1,773 |
$ |
(5) |
$ |
1,768 |
$ |
1,423 |
$ |
353 |
$ |
(12) |
$ |
1,764 |
$ |
(69) |
4.1 |
||||||||||||||||||||
|
(a) |
The amounts for the quarters ended December 31, 2018 and 2017 include adjustments for BD’s divestiture of its Advanced Bioprocessing business. The amounts for the quarter ended December 31, 2017 also include adjustments for BD’s divestitures of its soft tissue core needle biopsy product line and Bard’s divestiture of its Aspira® product line. |
|
(b) |
Reflects a reclassification of $26 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment. |
|
(c) |
Amounts represent revenues for the quarter ended December 31, 2017. |
|
(d) |
Under U.S. generally accepted accounting principles and as a result of Argentina’s highly inflationary economy, the functional currency of the Company’s operations in Argentina was the U.S. dollar for the quarter ended December 31, 2018. The total foreign currency translation impact above includes $7 million that was calculated by comparing local currency revenues in Argentina for the quarter ended December 31, 2018, translated using the prior-period exchange rate, to the reported U.S. dollar revenues for this same period. |
|
BECTON DICKINSON AND COMPANY |
|||||||||||||||||||||||||||||||||||||||||
|
SUPPLEMENTAL INFORMATION |
|||||||||||||||||||||||||||||||||||||||||
|
RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE – TOTAL |
|||||||||||||||||||||||||||||||||||||||||
|
Three Months Ended December 31, (continued) |
|||||||||||||||||||||||||||||||||||||||||
|
(Unaudited; Amounts in millions) |
|||||||||||||||||||||||||||||||||||||||||
|
A |
B |
C=A+B |
D |
E |
F |
G |
H=D+E+F+G |
I |
J=(C-H-I)/H |
||||||||||||||||||||||||||||||||
|
BD Reported |
Divestiture Adjustments (a) |
Comparable |
BD Reported (b) |
Bard Q1 (c) |
Intercompany Adjustment (d) |
Divestiture Adjustments (a) |
Comparable |
FX Impact (e) |
FXN % Change |
||||||||||||||||||||||||||||||||
|
2018 |
2018 |
2017 |
2017 |
2017 |
|||||||||||||||||||||||||||||||||||||
|
BD MEDICAL |
|||||||||||||||||||||||||||||||||||||||||
|
Medication Delivery Solutions (b) |
$ |
958 |
$ |
— |
$ |
958 |
$ |
742 |
$ |
213 |
$ |
(3) |
$ |
— |
$ |
952 |
$ |
(22) |
2.9 |
||||||||||||||||||||||
|
Medication Management Solutions |
624 |
— |
624 |
587 |
— |
— |
— |
587 |
(3) |
6.7 |
|||||||||||||||||||||||||||||||
|
Diabetes Care |
274 |
— |
274 |
277 |
— |
— |
— |
277 |
(5) |
0.6 |
|||||||||||||||||||||||||||||||
|
Pharmaceutical Systems |
280 |
— |
280 |
245 |
— |
— |
— |
245 |
(4) |
15.7 |
|||||||||||||||||||||||||||||||
|
TOTAL |
$ |
2,135 |
$ |
— |
$ |
2,135 |
$ |
1,852 |
$ |
213 |
$ |
(3) |
$ |
— |
$ |
2,062 |
$ |
(34) |
5.2 |
||||||||||||||||||||||
|
BD LIFE SCIENCES |
|||||||||||||||||||||||||||||||||||||||||
|
Preanalytical Systems |
$ |
393 |
$ |
— |
$ |
393 |
$ |
375 |
$ |
— |
$ |
— |
$ |
— |
$ |
375 |
$ |
(11) |
7.6 |
||||||||||||||||||||||
|
Diagnostic Systems |
382 |
— |
382 |
381 |
— |
— |
— |
381 |
(9) |
2.7 |
|||||||||||||||||||||||||||||||
|
Biosciences |
281 |
(9) |
273 |
289 |
— |
— |
(20) |
269 |
(6) |
3.6 |
|||||||||||||||||||||||||||||||
|
TOTAL |
$ |
1,056 |
$ |
(9) |
$ |
1,047 |
$ |
1,045 |
$ |
— |
$ |
— |
$ |
(20) |
$ |
1,025 |
$ |
(26) |
4.7 |
||||||||||||||||||||||
|
BD INTERVENTIONAL |
|||||||||||||||||||||||||||||||||||||||||
|
Surgery (b) |
$ |
348 |
$ |
— |
$ |
348 |
$ |
177 |
$ |
153 |
$ |
— |
$ |
(12) |
$ |
318 |
$ |
(2) |
10.0 |
||||||||||||||||||||||
|
Peripheral Intervention (b) |
337 |
— |
337 |
6 |
334 |
— |
— |
340 |
(5) |
0.6 |
|||||||||||||||||||||||||||||||
|
Urology and Critical Care |
285 |
— |
285 |
— |
267 |
— |
— |
267 |
(2) |
7.3 |
|||||||||||||||||||||||||||||||
|
TOTAL |
$ |
970 |
$ |
— |
$ |
970 |
$ |
183 |
$ |
755 |
$ |
— |
$ |
(12) |
$ |
925 |
$ |
(9) |
5.7 |
||||||||||||||||||||||
|
TOTAL REVENUES |
$ |
4,160 |
$ |
(9) |
$ |
4,152 |
$ |
3,080 |
$ |
968 |
$ |
(3) |
$ |
(33) |
$ |
4,012 |
$ |
(69) |
5.2 |
||||||||||||||||||||||
|
(a) |
The amounts for the quarters ended December 31, 2018 and 2017 include adjustments for BD’s divestiture of its Advanced Bioprocessing business. The amounts for the quarter ended December 31, 2017 also include adjustments for BD’s divestitures of its soft tissue core needle biopsy product line and Bard’s divestiture of its Aspira® product line. |
|
(b) |
Reflects a reclassification of $183 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment. |
|
(c) |
Amounts represent revenues for the quarter ended December 31, 2017. BD reported a Gore royalty amount, which was previously reported as revenues by Bard, as non-operating income in the current-year period. |
|
(d) |
Represents the elimination of revenues from the Medication Delivery Solutions unit which BD previously recognized from Bard as third-party revenues and that would be treated as intercompany revenues in the current-year period. |
|
(e) |
Under U.S. generally accepted accounting principles and as a result of Argentina’s highly inflationary economy, the functional currency of the Company’s operations in Argentina was the U.S. dollar for the quarter ended December 31, 2018. The total foreign currency translation impact above includes $7 million that was calculated by comparing local currency revenues in Argentina for the quarter ended December 31, 2018, translated using the prior-period exchange rate, to the reported U.S. dollar revenues for this same period. |
|
BECTON DICKINSON AND COMPANY |
||||||||||||||||||||||||||
|
SUPPLEMENTAL INFORMATION |
||||||||||||||||||||||||||
|
RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS |
||||||||||||||||||||||||||
|
(Unaudited) |
||||||||||||||||||||||||||
|
Three Months Ended December 31, |
||||||||||||||||||||||||||
|
2018 |
2017 |
Growth |
Foreign Currency Translation |
Foreign Currency Neutral Growth |
Growth % |
Foreign Currency Neutral Growth % |
||||||||||||||||||||
|
Reported Diluted Earnings (Loss) per Share |
$ |
2.05 |
$ |
(0.76) |
$ |
2.81 |
$ |
(0.14) |
$ |
2.95 |
369.7 |
% |
388.2 |
% |
||||||||||||
|
Purchase accounting adjustments ($379 million and $135 million pre-tax, respectively) (1) |
1.38 |
0.59 |
— |
|||||||||||||||||||||||
|
Restructuring costs ($41 million and $236 million pre-tax, respectively) (2) |
0.15 |
1.03 |
— |
|||||||||||||||||||||||
|
Integration costs ($73 million and $74 million pre-tax, respectively) (2) |
0.27 |
0.32 |
— |
|||||||||||||||||||||||
|
European regulatory initiative-related costs ($5 million pre-tax) (3) |
0.02 |
— |
— |
|||||||||||||||||||||||
|
Transaction costs ($1 million and $44 million pre-tax, respectively) (2) |
— |
0.19 |
— |
|||||||||||||||||||||||
|
Net impact of gain on sale of business ($(335) million pre-tax) (4) |
(1.22) |
— |
— |
|||||||||||||||||||||||
|
Financing impacts ($50 million pre-tax) (5) |
— |
0.22 |
— |
|||||||||||||||||||||||
|
Hurricane recovery costs ($7 million pre-tax) |
— |
0.03 |
— |
|||||||||||||||||||||||
|
Dilutive impact (6) |
— |
0.28 |
— |
|||||||||||||||||||||||
|
Impact of tax reform and income tax benefit of special items ($17 million and $135 million, respectively) (7) |
0.06 |
0.59 |
— |
|||||||||||||||||||||||
|
Adjusted Diluted Earnings per Share |
$ |
2.70 |
$ |
2.48 |
$ |
0.22 |
$ |
(0.15) |
$ |
0.37 |
8.9 |
% |
14.9 |
% |
||||||||||||
|
(1) |
Includes adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt. |
|
(2) |
Represents restructuring, integration and transaction costs associated with acquisitions. |
|
(3) |
Represents initial costs required to develop processes and systems to comply with emerging regulations such as the European Union Medical Device Regulation (“EUMDR”) and General Data Protection Regulation (“GDPR”). |
|
(4) |
Represents the pre-tax gain recognized during the period related to BD’s sale of its Advanced Bioprocessing business. |
|
(5) |
Represents financing impacts associated with the Bard acquisition. |
|
(6) |
Represents the dilutive impact of BD shares issued in May 2017, in anticipation of the Bard acquisition and BD shares issued as consideration transferred to acquire Bard. The adjusted diluted average shares outstanding (in thousands) was 218,997. |
|
(7) |
The amounts for the three months ended December 31, 2018 and 2017 reflect additional tax expense, net, of $51 million and $270 million, respectively, relating to new U.S. tax legislation. |
|
BECTON DICKINSON AND COMPANY |
|||||||||||
|
SUPPLEMENTAL INFORMATION |
|||||||||||
|
FY 2019 OUTLOOK RECONCILIATION |
|||||||||||
|
FY2018 |
FY2019 Outlook |
||||||||||
|
Revenues |
% Change |
FX Impact |
% Change FXN |
||||||||
|
BDX Revenue |
$ |
15,983 |
8.5% to 9.5% |
~2.0% |
10.5% to 11.5% |
||||||
|
Comparable Revenue Growth |
|||||||||||
|
BD Including Bard |
|||||||||||
|
FY2018 |
FY2019 Outlook |
||||||||||
|
Revenues |
% Change FXN Comparable |
||||||||||
|
BDX As Reported Revenue |
$ |
15,983 |
|||||||||
|
Bard Q1 |
968 |
||||||||||
|
Intercompany Adjustment |
(3) |
||||||||||
|
Divestiture Adjustment (1)(2) |
(124) |
||||||||||
|
BDX NewCo Comparable Revenue |
$ |
16,824 |
5.0% to 6.0% |
||||||||
|
FXN – Foreign Currency Neutral |
|||||||||||
|
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2019 OUTLOOK RECONCILIATION (continued) |
|||||||||||
|
FY2018 |
FY2019 Outlook |
||||||||||
|
Revenues |
% Change FXN Comparable |
||||||||||
|
BD Medical As Reported Revenue |
$ |
8,616 |
|||||||||
|
Bard Q1 |
213 |
||||||||||
|
Intercompany Adjustment |
(3) |
||||||||||
|
BD Medical Comparable Revenue |
8,826 |
5.0% to 6.0% |
|||||||||
|
BD Life Sciences As Reported Revenue |
$ |
4,330 |
|||||||||
|
Divestiture Adjustment (1) |
(106) |
||||||||||
|
BD Life Sciences Comparable Revenue |
$ |
4,224 |
4.0% to 5.0% |
||||||||
|
BD Interventional as Reported Revenue |
$ |
3,037 |
|||||||||
|
Bard Q1 |
755 |
||||||||||
|
Divestiture Adjustment (2) |
(18) |
||||||||||
|
BD Interventional Comparable Revenue |
$ |
3,774 |
6.0% to 7.0% |
||||||||
|
FXN – Foreign Currency Neutral |
|||||||||||
|
(1) Excludes the impact from the divestiture of BD’s Advanced Bioprocessing business. |
|||||||||||
|
(2) Excludes the impact from the divestitures of BD’s soft tissue core needle biopsy product line and Bard’s Aspira product line of tunneled home drainage catheters and accessories. |
|||||||||||
|
BECTON DICKINSON AND COMPANY |
|||||||||||
|
FY2019 Outlook |
|||||||||||
|
Full Year |
Full Year |
% Increase |
|||||||||
|
Reported Fully Diluted Earnings per Share |
$ |
0.60 |
|||||||||
|
Purchase accounting adjustments ($1.733 billion pre-tax) (1) |
6.55 |
||||||||||
|
Restructuring costs ($344 million pre-tax) (2) |
1.30 |
||||||||||
|
Integration costs ($344 million pre-tax) (2) |
1.30 |
||||||||||
|
Transaction costs ($56 million pre-tax) (3) |
0.21 |
||||||||||
|
Financing impacts ($49 million pre-tax) (4) |
0.19 |
||||||||||
|
Hurricane recovery costs ($17 million pre-tax) |
0.07 |
||||||||||
|
Losses on debt extinguishment ($16 million pre-tax) (5) |
0.06 |
||||||||||
|
Net impact of gain on sale of investment and asset impairments ($(151) million pre-tax) (6) |
(0.57) |
||||||||||
|
Dilutive Impact (7) |
0.30 |
||||||||||
|
Impact of tax reform and income tax benefit of special items ($265 million) (8) |
1.00 |
||||||||||
|
Adjusted Fully Diluted Earnings per Share |
$ |
11.01 |
$12.05 to 12.15 |
~10% |
|||||||
|
Estimated FX Impact |
~3.5% |
||||||||||
|
Adjusted FXN Growth |
13% – 14% |
||||||||||
|
FXN – Foreign Currency Neutral |
|
|
(1) |
Includes adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt. The amount in 2018 also included a fair value step-up adjustment of $478 million recorded relative to Bard’s inventory on the acquisition date. |
|
(2) |
Represents restructuring and integration costs associated with the Bard and CareFusion acquisitions, as well as restructuring costs associated with other portfolio rationalization initiatives. |
|
(3) |
Represents transaction costs primarily associated with the Bard acquisition. |
|
(4) |
Represents financing impacts associated with the Bard acquisition. |
|
(5) |
Represents losses recognized upon the extinguishment of certain long-term senior notes. |
|
(6) |
Represents the net amount recognized in the period related to BD’s sale of its non-controlling interest in Vyaire Medical, partially offset by $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit as well as $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit. |
|
(7) |
Represents the dilutive impact of BD shares issued in May 2017, in anticipation of the Bard acquisition and BD shares issued as consideration transferred to acquire Bard. The adjusted diluted average shares outstanding (in thousands) was 260,758. |
|
(8) |
Includes additional tax expense, net, of $640 million relating to new U.S. tax legislation. |
SOURCE BD (Becton, Dickinson and Company)
